No Data
No Data
Instil Bio Is Maintained at Outperform by Baird
Instil Bio Is Maintained at Outperform by Baird
Baird: Maintaining the Instil Bio (TIL.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $54.00 to $32.00.
Baird: Maintaining the Instil Bio (TIL.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $54.00 to $32.00.
Baird Maintains Outperform on Instil Bio, Lowers Price Target to $32
Baird analyst Jack Allen maintains Instil Bio with a Outperform and lowers the price target from $54 to $32.
Instil Bio, Inc. Q1 Loss Decreases
Instil Bio | 10-Q: Quarterly report
Instil Bio Q1 2024 GAAP EPS $(2.39) Misses $(2.23) Estimate
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) by 7.17 percent.